Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Australian Clinical Labs Ltd ( (AU:ACL) ) has provided an update.
Australian Clinical Labs Ltd has an on-market share buy-back program in place for its ordinary fully paid shares traded under the ASX code ACL. The company has been steadily repurchasing stock as part of this capital management initiative.
The latest update reports that a total of 7,365,593 shares had been bought back before the previous day, with a further 104,585 shares repurchased on the previous trading day. This ongoing activity signals continued execution of the buy-back strategy, which may influence the company’s capital structure and shareholder value over time.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$2.20 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd is a healthcare diagnostics company that operates pathology and laboratory testing services across Australia. It provides a range of clinical laboratory tests for healthcare providers, supporting patient diagnosis, treatment, and monitoring in the medical services market.
Average Trading Volume: 813,579
Technical Sentiment Signal: Sell
Current Market Cap: A$390.6M
See more insights into ACL stock on TipRanks’ Stock Analysis page.